摘要
肥胖是一种流行病,与心血管疾病相关,增加了总死亡率。然而,最近已经证明癌症是OBEs的意外后果。伊蒂。在大多数的研究中,它是用身体质量指数(BMI)来评估的:高BMI会增加癌症的风险,降低许多实体肿瘤的存活率。肥胖c的主要生物学和临床主题这里介绍和讨论了Ancer患者。高胰岛素血症和胰岛素样生长因子(IGFS)是癌症与肥胖之间最重要的联系。然而,脂肪组织(AT)ALSO产生性激素、促炎细胞因子和缺氧,从而促进肿瘤的发生和发展.。肥胖癌症患者的主要临床关注之一是c的风险。化疗相关的毒性。先前的研究表明肥胖患者与非肥胖患者相比没有显著增加的毒性。因此,发病率越来越高,科学性也越来越强。肥胖知识应该促使研究人员研究肥胖癌症患者的个性化治疗,而不是单纯的化疗“去增强”。它已经被妖魔化了减肥可以降低癌症风险,改善治疗依从性。因此,社会政治以及治疗肥胖的方法可能会影响癌症的风险、治疗和生存。
关键词: 肥胖,体重指数,胰岛素,脂肪组织,癌症风险,心血管疾病。
图形摘要
Current Cancer Drug Targets
Title:Obesity and Cancer: Biological Links and Treatment Implications
Volume: 18 Issue: 3
关键词: 肥胖,体重指数,胰岛素,脂肪组织,癌症风险,心血管疾病。
摘要: Obesity is an epidemic disease and correlates with cardiovascular diseases increasing the overall mortality. However, it has been recently demonstrated that cancer is an unexpected consequence of obesity. In most of the studies, it is evaluated with body mass index (BMI): high BMI increases cancer risk and reduces survival of many solid tumors. The main biologic and clinic topics regarding obese cancer patients are here presented and discussed. Hyperinsulinemia and Insulin-like Growth Factors (IGFs) are among the most important links between cancer and obesity. However, adipose tissue (AT) also produces sex hormones, pro-inflammatory cytokines and hypoxia which in turn promote initiation and progression of tumors. One of the major clinic concern about obese cancer patients is the risk of chemotherapy-related toxicity. Previous studies showed that obese patients do not experience significant increased toxicity compared to non-obese patients. Thus, the increasing incidence and scientific knowledge of obesity should prompt the researchers to study for personalization of therapy in obese patients with cancer rather than for the simple chemotherapy “depotentiation”. It has been demonstrated that weight loss reduces cancer risk and can ameliorate compliance to therapy. Thus, social politics as well as therapies against obesity may impact on cancer risk, treatment and survival.
Export Options
About this article
Cite this article as:
Obesity and Cancer: Biological Links and Treatment Implications, Current Cancer Drug Targets 2018; 18 (3) . https://dx.doi.org/10.2174/1568009617666170330125619
DOI https://dx.doi.org/10.2174/1568009617666170330125619 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer
Current Cancer Drug Targets Contemporary Review of Drugs Used to Treat Obesity
Cardiovascular & Hematological Agents in Medicinal Chemistry Chemoradiotherapy of Human Tumors: Novel Approaches from Nanomedicine
Current Pharmaceutical Design Mutual Modulation of Femarelle and Vitamin D Analog Activities in Human Derived Female Cultured Osteoblasts
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Micro Arrays and Biochips: Applications and Potential in Genomics and Proteomics
Current Genomics The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications
Current Cancer Drug Targets Natural Products as Aromatase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Expression Profile of Endoglin in Different Grades of Endometrial Cancer
Current Pharmaceutical Biotechnology Metallodrug Conjugates with Steroids and Selective Estrogen Receptor Modulators (SERM)
Current Medicinal Chemistry Arsenic Trioxide Exerts Anti-lung Cancer Activity by Inhibiting Angiogenesis
Current Cancer Drug Targets Targeting CD147 is a Novel Strategy for Antitumor Therapy
Current Pharmaceutical Design Role of Metabolic Enzymes P450 (CYP) on Activating Procarcinogen and their Polymorphisms on the Risk of Cancers
Current Drug Metabolism The Role of Insulin Resistance and Hyperinsulinemia in Cancer Causation
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Raloxifene
Current Drug Targets Targeting Drug-Resistant Prostate Cancer with Dual PI3K/mTOR Inhibition
Current Medicinal Chemistry HER2-Mediated Anticancer Drug Delivery: Strategies to Prepare Targeting Ligands Highly Specific for the Receptor
Current Medicinal Chemistry Suicide Gene Therapy Against Malignant Gliomas by the Local Delivery of Genetically Engineered Umbilical Cord Mesenchymal Stem Cells as Cellular Vehicles
Current Gene Therapy Melanoma Immunotherapy: Past, Present, and Future
Current Pharmaceutical Design Pleiotropic Effects of Cathepsin D
Endocrine, Metabolic & Immune Disorders - Drug Targets